Quanterix Launches LucentAD Test To Assist In Evaluation Of Patients Experiencing Cognitive Symptoms Consistent With The Early Signs Of Alzheimer's Disease
Portfolio Pulse from Benzinga Newsdesk
Quanterix has launched LucentAD, a test designed to assist in the evaluation of patients experiencing cognitive symptoms consistent with early signs of Alzheimer's disease. The test is available through a healthcare provider's order. Lucent Diagnostics plans to announce additional tests for Alzheimer's and other neurological disorders.

July 06, 2023 | 9:39 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Quanterix's launch of the LucentAD test could potentially increase the company's market share in the healthcare sector, particularly in the diagnosis and management of Alzheimer's and other neurological disorders.
The launch of the LucentAD test by Quanterix is directly related to the company's product portfolio and could potentially increase its market share in the healthcare sector. The test, which is designed to assist in the evaluation of patients experiencing cognitive symptoms consistent with early signs of Alzheimer's disease, fills a significant need in the market. Furthermore, the announcement of additional tests for Alzheimer's and other neurological disorders could further strengthen the company's position in this sector.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100